Lactobacillus reuteri
What makes Lactobacillus reuteri distinct
Lactobacillus reuteri is a probiotic species with a genuinely interesting but highly strain-specific evidence base. Unlike broad category-level probiotic marketing, the clinically relevant effects of L. reuteri do not apply across the species as a whole. The best-studied strain for infant colic is DSM 17938. The strains used in oral health studies are often ATCC PTA 5289 combined with DSM 17938. These are not interchangeable with generic products labelled simply as Lactobacillus reuteri.
L. reuteri is naturally present in some human and animal gastrointestinal tracts and produces a number of bioactive compounds, including reuterin, that have attracted mechanistic interest. It also appears to interact with motility, inflammation, and mucosal signalling pathways. These mechanisms are biologically plausible, but as with all probiotics, mechanism does not substitute for clinical evidence.
The strain designation is critical. Evidence for DSM 17938 in infant colic does not transfer to another L. reuteri strain. Evidence for ATCC PTA 5289 in periodontal adjunctive care does not justify choosing any oral probiotic labelled L. reuteri. This is the central interpretive principle.
What the evidence shows
Infant colic in breastfed infants. This is the strongest and most clinically relevant indication. Multiple randomised trials and an individual participant data meta-analysis show that DSM 17938 reduces crying time in breastfed infants with colic. The effect is clinically meaningful and sufficiently replicated to justify a Moderate rating. The important limitation is that this effect is not established in formula-fed infants, where the evidence is weaker and less consistent.
Periodontal disease and gingival inflammation. Specific L. reuteri strains, particularly ATCC PTA 5289 often used with DSM 17938, improve periodontal indices when added to standard non-surgical therapy such as scaling and root planing. The effect is adjunctive rather than standalone. Results are directionally positive but heterogeneity between studies remains substantial, which limits confidence.
H. pylori eradication adjunct use. Several trials suggest that L. reuteri may reduce antibiotic-related side effects during eradication therapy and may modestly improve eradication rates. The evidence is not robust enough to support strong claims, and it is weaker than for more established adjuncts in this context. It should not be framed as treatment for H. pylori itself.
General digestive and immune outcomes. This is where commercial overclaim becomes a problem. Evidence for adult functional GI symptoms is inconsistent. Evidence for immune and respiratory infection outcomes is not strong enough to support general claims. L. reuteri is not a broadly proven gut-health or immune-health probiotic.
Practical considerations
For infant colic, the relevant preparation is DSM 17938 at approximately 1 x 10^8 CFU daily. This is usually delivered as drops and has been studied in breastfed infants over periods of several weeks.
For oral health indications, strain selection and route of delivery matter. Chewable tablets or lozenges containing strains such as ATCC PTA 5289 have been used as adjuncts to periodontal therapy. This is a different use case from infant oral drops and should not be treated as interchangeable.
Because efficacy is strain-specific, product labels that omit the strain designation are much less informative. A label stating only “Lactobacillus reuteri” is not enough to infer clinical relevance.
Safety
L. reuteri is generally well tolerated in healthy infants and adults. In infant colic studies, it has shown a good short-term safety profile. In dental and adult GI studies, adverse effects are uncommon and usually mild.
As with all live probiotics, the main safety caveat is population-specific rather than general. Immunocompromised individuals, critically ill patients, and those with compromised gut barrier function should not use live probiotics without medical supervision. Rare invasive infections have been reported with probiotics as a class.
What can reasonably be concluded
Lactobacillus reuteri has a meaningful but narrow evidence base. The clearest indication is DSM 17938 for infant colic in breastfed infants, where the evidence is replicated and clinically useful. Periodontal adjunctive use is promising and moderately supported for selected strains, but should be understood as an addition to standard care rather than a replacement for it.
Broader digestive wellness, immune support, and general health claims are not supported by the current clinical evidence. The key practical point is strain specificity: a product labelled L. reuteri is not enough. The relevant question is always which strain, for which indication, in which population.
Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.